ANXA2 and pachyonychia congenita: Further evidence of the potential value of ANXA2 as a therapeutic target for PC was provided by Foley et al. and Keklikoglou et al. The former found that ANXA2 is essential for PDAC metastasis in a transgenic mouse model of PDAC, and that the gene expression, as well as the secretion of semaphorin 3D, is increased in PDAC, inducing its invasion capacity.